Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Lasker Awards Given to Researchers in Virology, Physiology

By Stephanie Guzowski | September 13, 2016

The Albert and Mary Lasker Foundation today named seven scientists as winners of its annual awards, which honor basic medical research, clinical research and special achievement. Each category will receive $250,000.

The Lasker-DeBakey Clinical Medical Research Award went to two virologists — Ralf F. W. Bartenschlager of the University of Heidelberg in Germany and Charles M. Rice of Rockefeller University in New York — for creating a system to replicate the hepatitis C virus in the laboratory, and to Michael Sofia, an industry scientist, for using the system to develop the hepatitis C drug, now sold as Sovaldi.

Scientists first sequenced the genome of the hepatitis C virus in 1989. Researchers then believed they could insert that newly sequenced RNA into cultured cells and watch it replicate — but this approach was not so simple.

In the 1990s, Bartenschlager’s and Rice’s labs discovered a method to replicate fragments of the hepatitis C virus’s RNA in lab-grown cells. The researchers’ discoveries, which were published in journal articles in 1999 and 2000, happened after many failed attempts, since hepatitis C virus is well-known for being difficult to replicate in a lab setting.

Afterward, pharmaceutical researchers targeting hepatitis C used Bartenschlager’s and Rice’s replication method in the drug discovery process. In 2005, Sofia joined a small biotech company called Pharmasset, where he developed a chemical that blocked hepatitis C replication. His work led to the development of a new oral drug, sofosbuvir, marketed as Sovaldi. Sovaldi was approved by the FDA in 2013 to treat hepatitis C virus, which affects about 3.5 million Americans, and as many as 170 million people worldwide.

Sovaldi can cure patients, without severe side effects. Since Sovaldi was approved, other hepatitis C treatments have come on the market, including Gilead’s Harvoni, which has cure rates of 94 percent to 99 percent in eight to 12 weeks of therapy. Despite these successes, hepatitis drugs are high in price, with some between $54,000 and $94,000 for a full course of treatment.

A team of researchers from Harvard University, Johns Hopkins University, and the Francis Crick Institute were also honored for their discovery of the pathway by which human cells sense and adapt to changes in oxygen availability. Their work led to the discovery of a protein, HIF-1, that emerged when oxygen was scarce and then activated a large network of genes. Their discovery has had implications in treating heart disease and cancer.


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE